Published in final edited form as:

Am J Med Genet B Neuropsychiatr Genet. 2010 June 5; 153B(4): 955–959. doi:10.1002/ajmg.b.31053.

Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease

JSK Kauwe^{1,§}, S Bertelsen¹, K Mayo¹, C Cruchaga¹, R Abraham², P Hollingworth², D Harold², MJ Owen², J Williams², S Lovestone³, JC Morris¹, AM Goate¹, and Alzheimer's Disease Neuroimaging Initiative*

¹ Departments of Psychiatry & Neurology, Washington University School of Medicine, St. Louis, MO 63110

² MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine, School of Medicine, Cardiff University, Cardiff, Cardiff CF14 4XN, UK

³ Department of Neuroscience, Institute of Psychiatry, Kings College, London, UK

Abstract

Alzheimer's disease (AD) is a complex disease that is likely influenced by many genetic and environmental factors. Citing evidence that iron may play a role in AD pathology, Robson et al. (2004) reported that epistatic interaction between rs1049296 (P589S) and rs1800562 (C282Y) in the hemochromatosis gene (*HFE*) results in significant association with risk for AD. In this study we attempted to replicate their findings in a total of 1166 cases and 1404 controls from three European and European American populations. Allele and genotype frequencies were consistent across the three populations. Using Synergy Factor Analysis and Logistic Regression analysis we tested each population and the combined sample for interactions between these two SNPs and risk for AD. We observed significant association between bi-carriers of the minor alleles of rs1049296 and rs1800562 in the combined sample using Synergy Factor Analysis ($p=0.0016$, synergy factor=2.71) and adjusted Synergy Factor Analysis adjusting for age and presence of the APOE epsilon 4 allele ($p=0.002$, OR=2.4). These results validate those of the previous report and support the hypothesis that iron transport and regulation play a role in AD pathology.

Keywords

Transferrin; Hemochromatosis gene; Alzheimer's disease; epistasis; genetic association

Alzheimer's disease (AD) is a complex disease that is likely influenced by many genetic and environmental factors. Recent studies using meta-analyses and genome-wide association studies (GWAS) have provided increasing evidence for new genetic risk factors (Beecham and others 2009; Bertram and others 2008; Carrasquillo and others 2009; Coon and others 2007; Feulner and others 2009; Harold and others 2009; Lambert and others 2009; Li and others 2008). Evidence from AlzGene (alzgene.org) meta-analyses provides support for

Corresponding Author and address for correspondence, John S.K. Kauwe, PhD, Assistant Professor, Department of Biology, Brigham Young University, Provo, UT 84602, Kauwe@byu.edu, Phone: 801-422-2993, Fax: 801-422-0090, Alison M. Goate, PhD, Samuel & Mae S. Ludwig Professor, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110. goatea@psychiatry.wustl.edu Phone: 314-362-8691 Fax: 314-747-2983.

*Current address, John S.K. Kauwe, PhD, Assistant Professor, Department of Biology, Brigham Young University, Provo, UT 84602,

*Some of the data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI investigators include (complete listing available at http://www.loni.ucla.edu/ADNI/About/About_Investigators.shtml).

several risk variants with small effect sizes (Bertram and others 2007). Two recent studies investigated 29 such variants from the Alzgene meta-analyses for association in a large family based sample (Schjeide and others 2009) and in samples in which cerebrospinal fluid (CSF) biomarkers have been measured including amyloid-beta ($A\beta$) levels (Kauwe and others 2009). Among the consistent findings, one SNP in *TF*, rs1049296 that results in a missense coding polymorphism (P589S), showed significant association in both studies (Kauwe and others 2009; Schjeide and others 2009). Like many other genetic associations, results from various studies with rs1049296 have yielded both positive (Namekata and others 1997; Robson and others 2004; Schjeide and others 2009; Van Landeghem and others 1998; van Rensburg and others 1993; Zambenedetti and others 2003) and negative results (Blazquez and others 2007; Emahazion and others 2001; Hussain and others 2002; Kim and others 2001; Lleo and others 2002; Reiman and others 2007; Rondeau and others 2006). Such inconsistency may indicate that the association is spurious, or that the studies lack statistical power (Bertram and Tanzi 2004). It has also been suggested that lack of replication in genetic association studies is not surprising given the extent of genetic and environmental heterogeneity (Gorroochurn and others 2007) and may even be a “signature of epistasis” (Moore and Williams 2005; Wade 2001). Evidence for epistatic interaction between *APOE e4* and genetic variation in *BACE* has been consistently replicated, though the nature of the interaction has yet to be characterized (Combarros and others 2008). It has also been reported that a synergy between rs1049296 and rs1800562 in the hemochromatosis gene (*HFE*) has strong association with risk for AD, with individuals that carry the minor allele at both loci having 5-fold greater risk for disease using both Synergy Factor Analysis (SFA) and logistic regression (Robson and others 2004). Both of these variants are amino acid substitutions (rs1049296 is P589S; rs1800562 is C282Y). In this study we attempt to replicate the report of epistasis between rs1049296 and rs1800562 and association with risk for LOAD in a total of 1166 cases and 1404 controls from three European and European American samples.

The case control series for this study were collected at three different sites. Basic sample characteristics for each series are shown in table I. The Washington University (WU) case-control series used in this study was collected through the WU Alzheimer's Disease Research Center (ADRC) patient registry. Cases in this series received a diagnosis of dementia of the Alzheimer's type (DAT), using criteria equivalent to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, modified slightly to include AD as a diagnosis for individuals aged >90 years (Berg and others 1998; McKhann and others 1984). A total of 331 unrelated DAT cases with a minimum age at onset (AAO) of 60 years were recruited for the study. DNA from 385 age- and sex-matched nondemented controls aged >60 years at assessment were obtained through the ADRC.

We also used clinical data and DNA samples from 631 individuals with late-onset AD and 769 control subjects ascertained from both community and hospital settings in the UK collected as part of the Medical Research Council genetic resource for late-onset AD (MRC Sample). A detailed description of the ascertainment and assessment of this sample has been reported elsewhere (Morgan and others 2007).

Data from 199 AD cases and 188 controls from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were used. Data used in the preparation of this article were obtained from the ADNI database on May 15th, 2008 (www.loni.ucla.edu/ADNI). The Principle Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and University of California – San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal

of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research -- approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people with early AD to be followed for 2 years." For up-to-date information see www.adni-info.org. Finally, genotype counts from Robson et al (2004) were used in our meta-analysis (Robson and others 2004).

Rs1049296 and rs1800562 were genotyped using Sequenom genotyping technology. Single SNP allelic associations were evaluated using Fisher's exact test and genotypic associations were evaluated with logistic regression using the additive, dominant and recessive models. Synergy factor analysis (SFA) and adjusted SFA were used to evaluate the size and significance of the effect of interaction between rs1049296 and rs1800562 and risk for AD with minor allele non-carriers as the reference group (Combarros and others 2008; Cortina-Borja and others 2009; Lehmann and others 2001; Robson and others 2004).

Neither rs1049296 nor rs1800562 showed association with risk for AD in single SNP tests using the additive model (table II). Analyses using the recessive and dominant genetic models and models using *APOE e4* as a covariate also failed to detect association in the single SNP tests. Allele and genotype frequencies appeared consistent between males and females. SFA in the WU series was significant with a p-value of 0.0032 and a synergy factor of 5.99 (95% Confidence Interval (CI): 1.82-19.69) for bi-carriers using non-carriers as the reference. SFA in the MRC and ADNI samples was not significant (table III) but showed trends in the same direction. A large number of samples from the WU and MRC were recently included in a genome-wide association study. Extensive analyses using Eigenstrat (Price and others 2006) showed no evidence of population stratification between these two samples (Harold and others 2009). Allele and genotype frequencies for each SNP were very similar between the three samples (table II). A combined analysis of our samples shows significant association with SFA unadjusted for covariates and adjusted SFA including site, gender, age and *APOE e4* as covariates (table III). SFA unadjusted for covariates using our three samples and data from the initial report (Robson and others 2004), is also significant ($p=5.15 \times 10^{-3}$, OR=2.72; table 3).

Our findings in the WU series and the combined sample support the previous observation of synergy between rs1049296 and rs1800562 as risk factors for AD. While there were differences in the level of association in the individuals sample (possibly due to differences in the sample populations and genetic or clinical heterogeneity; table III) the unadjusted SF in our combined sample for individuals that carry at least one minor allele at each locus is 2.71 (CI: 1.46-5.05) and the adjusted SF including age and *APOE e4* as covariates was 2.4 (CI: 1.38-3.94). This is lower than the SF of 5.1 from the original report but still indicates a higher level of risk for the bi-carriers of these alleles. Individuals that carry the minor allele at only one of these loci do not show significantly increased risk for AD (table II). In this study bi-carriers make up about 4% of the AD sample. It has been proposed that these individuals may be at higher risk of AD due to increased redox-active iron and oxidative stress (Lehmann and others 2006; Robson and others 2004). Rs1800562 in *HFE* is known to cause iron-overload and hemochromatosis in individuals homozygous for the allele (OMIM-235200). Wild type *HFE* binds transferrin receptor 1 (TfR1). *HFE* with the minor allele "A" of rs1800562 has much lower affinity for TfR1, leaving the receptor free to bind TF with high affinity (Feder and others 1998). This may result in increased uptake of TF bound iron, causing over-absorption of dietary iron and iron deposition in various tissues (Townsend and Drakesmith 2002). Wild type TF is important for iron transport and may be involved in limiting the amyloid aggregation process (Giunta and others 2004). While rs1049296 does not appear to affect the ability of TF to bind iron (Zatta and others 2005), the minor allele "T" shows significant association with increased A β 42/A β 40 ratio in the cerebrospinal fluid (Kauwe and others 2009). Our current knowledge of rs1049296 and

rs1800562 implicate both effects on A β and iron-overload as possible mechanisms for AD risk. In summary our findings provide support for previous reports of synergy between rs1049296 and rs1800562 as risk variants for AD and support for the hypothesis that iron transport and regulation play a role in AD pathology.

Acknowledgments

This work was supported by the National Institute on Aging (P50-AG05681, J.C.M.; P01-AG03991, J.C.M.; P01-AG026276, J.C.M.; R01-AG16208, A.M.G.; P30-N5057105, D.M.H.; 1-TL1-RR024995-01 and 1-KL2-RR024994-01, Washington University) the Barnes Jewish Foundation and the American Health Assistance Foundation (A.M.G.). This publication was made possible in part by grant number UL1 RR024992 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. During the time this research was performed J.S.K.K. was a Hope Center Fellow supported by the Hope Center for Neurological Disorders and National Institutes of Health Grant T32 MH14677. C.C. is supported by a fellowship from the "Fundacion Alfonso Martin Escudero". The authors gratefully acknowledge the individuals who participated in this study. The authors also acknowledge the contributions of the Genetics, Clinical, Psychometric, and Biostatistics Cores of the Washington University Alzheimer's Disease Research Center.

Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI; Principal Investigator: Michael Weiner; NIH grant U01 AG024904) is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and through generous contributions from the following: Pfizer Inc., Wyeth Research, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck & Co. Inc., AstraZeneca AB, Novartis Pharmaceuticals Corporation, Alzheimer's Association, Eisai Global Clinical Development, Elan Corporation plc, Forest Laboratories, and the Institute for the Study of Aging, with participation from the U.S. Food and Drug Administration. Industry partnerships are coordinated through the Foundation for the National Institutes of Health. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles (<http://www.loni.ucla.edu/ADNI/>).

References

- Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, Pericak-Vance MA. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. *Am J Hum Genet.* 2009; 84(1):35–43. [PubMed: 19118814]
- Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. *Arch Neurol.* 1998; 55(3):326–35. [PubMed: 9520006]
- Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet.* 2008; 83(5):623–32. [PubMed: 18976728]
- Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat Genet.* 2007; 39(1):17–23. [PubMed: 17192785]
- Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too many genes? *Hum Mol Genet.* 2004; 13(1):R135–41. [PubMed: 14764623]
- Blazquez L, De Juan D, Ruiz-Martinez J, Emparanza JJ, Saenz A, Otaegui D, Sistiaga A, Martinez-Lage P, Lamet I, Samaranch L, et al. Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population. *Neurobiol Aging.* 2007; 28(12):1941–3. [PubMed: 17011669]
- Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglia GD, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. *Nat Genet.* 2009
- Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ. Epistasis in sporadic Alzheimer's disease. *Neurobiol Aging.* 2008

- Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. *J Clin Psychiatry*. 2007; 68(4):613–8. [PubMed: 17474819]
- Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ. The synergy factor: a statistic to measure interactions in complex diseases. *BMC Res Notes*. 2009; 2:105. [PubMed: 19527493]
- Emahazion T, Feuk L, Jobs M, Sawyer SL, Fredman D, St Clair D, Prince JA, Brookes AJ. SNP association studies in Alzheimer's disease highlight problems for complex disease analysis. *Trends Genet*. 2001; 17(7):407–13. [PubMed: 11418222]
- Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. *Proc Natl Acad Sci U S A*. 1998; 95(4):1472–7. [PubMed: 9465039]
- Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, Kuhn KA, Krawczak M, Schreiber S, Nikolaus S, et al. Examination of the current top candidate genes for AD in a genome-wide association study. *Mol Psychiatry*. 2009
- Giunta S, Galeazzi R, Valli MB, Corder EH, Galeazzi L. Transferrin neutralization of amyloid beta 25–35 cytotoxicity. *Clin Chim Acta*. 2004; 350(1-2):129–36. [PubMed: 15530469]
- Gorroochurn P, Hodge SE, Heiman GA, Durner M, Greenberg DA. Non-replication of association studies: “pseudo-failures” to replicate? *Genet Med*. 2007; 9(6):325–31. [PubMed: 17575498]
- Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvin V, Dowzell K, Williams A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet*. 2009
- Hussain RI, Ballard CG, Edwardson JA, Morris CM. Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. *Neurosci Lett*. 2002; 317(1):13–6. [PubMed: 11750985]
- Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. *Neurogenetics*. 2009; 10(1):13–7. [PubMed: 18813964]
- Kim KW, Jhoo JH, Lee JH, Lee DY, Lee KU, Youn JY, Woo JI. Transferrin C2 variant does not confer a risk for Alzheimer's disease in Koreans. *Neurosci Lett*. 2001; 308(1):45–8. [PubMed: 11445282]
- Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet*. 2009
- Lehmann DJ, Williams J, McBroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. *Neuroscience*. 2001; 108(4):541–54. [PubMed: 11738493]
- Lehmann DJ, Worwood M, Ellis R, Wimbust VL, Merryweather-Clarke AT, Warden DR, Smith AD, Robson KJ. Iron genes, iron load and risk of Alzheimer's disease. *J Med Genet*. 2006; 43(10):e52. [PubMed: 17047092]
- Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. *Arch Neurol*. 2008; 65(1):45–53. [PubMed: 17998437]
- Lleo A, Blesa R, Angelopoulos C, Pastor-Rubio P, Villa M, Oliva R, Buñill E. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2002; 72(6):820–1. [PubMed: 12023437]
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984; 34(7):939–44. [PubMed: 6610841]
- Moore JH, Williams SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. *Bioessays*. 2005; 27(6):637–46. [PubMed: 15892116]

- Morgan AR, Turic D, Jehu L, Hamilton G, Hollingworth P, Moskvina V, Jones L, Lovestone S, Brayne C, Rubinsztein DC, et al. Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease. *Am J Med Genet B Neuropsychiatr Genet.* 2007; 144B(6):762–70. [PubMed: 17373700]
- Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer's disease. *Hum Genet.* 1997; 101(2):126–9. [PubMed: 9402955]
- Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet.* 2006; 38(8): 904–9. [PubMed: 16862161]
- Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. *Neuron.* 2007; 54(5):713–20. [PubMed: 17553421]
- Robson KJ, Lehmann DJ, Wimbush VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, Warden DR, Smith AD. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. *J Med Genet.* 2004; 41(4):261–5. [PubMed: 15060098]
- Rondeau V, Iron A, Letenneur L, Commenges D, Duchene F, Arveiler B, Dartigues JF. Analysis of the effect of aluminum in drinking water and transferrin C2 allele on Alzheimer's disease. *Eur J Neurol.* 2006; 13(9):1022–5. [PubMed: 16930371]
- Schjeide BM, McQueen MB, Mullin K, Divito J, Hogan MF, Parkinson M, Hooli B, Lange C, Blacker D, Tanzi RE, et al. Assessment of Alzheimer's disease case-control associations using family-based methods. *Neurogenetics.* 2009; 10(1):19–25. [PubMed: 18830724]
- Townsend A, Drakesmith H. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. *Lancet.* 2002; 359(9308):786–90. [PubMed: 11888608]
- Van Landeghem GF, Sikstrom C, Beckman LE, Adolfsson R, Beckman L. Transferrin C2, metal binding and Alzheimer's disease. *Neuroreport.* 1998; 9(2):177–9. [PubMed: 9507951]
- van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ. Increased frequency of the transferrin C2 subtype in Alzheimer's disease. *Neuroreport.* 1993; 4(11):1269–71. [PubMed: 8219026]
- Wade MJ. Epistasis, complex traits, and mapping genes. *Genetica.* 2001; 112-113:59–69. [PubMed: 11838787]
- Zambenedetti P, De Bellis G, Biunno I, Musicco M, Zatta P. Transferrin C2 variant does confer a risk for Alzheimer's disease in caucasians. *J Alzheimers Dis.* 2003; 5(6):423–7. [PubMed: 14757931]
- Zatta P, Messori L, Mauri P, van Rensburg SJ, van Zyl J, Gabrielli S, Gabbiani C. The C2 variant of human serum transferrin retains the iron binding properties of the native protein. *Biochim Biophys Acta.* 2005; 1741(3):264–70. [PubMed: 15975770]

Table I

Sample characteristics. The number of individuals, age (mean age at onset for cases, mean age at last assessment for controls), percent of the sample that is female (%female) and percent of the sample that carries the *APOE e4* allele (% e4 pos) is shown for the Washington University (WU), Medical Research Council (MRC) and Alzheimer's disease Neuroimaging Initiative (ADNI) series.

	N	age	%female	%e4 pos
WU				
Cases	331	76.6	0.62	53.6
Controls	385	77.7	0.61	23.2
MRC				
Cases	631	75.7	0.73	62.2
Controls	769	76.1	0.62	23.4
ADNI				
Cases	199	71.8	0.56	65.0
Controls	188	77.7	0.55	27.8

Allele and genotype frequencies and p-values from allelic and genotypic associations. Minor allele frequencies in cases and controls (MAF), genotype frequencies (Geno. Freq) and P-values for allelic association from Fisher's Exact test and genotypic association from logistic regression using the additive genetic model are shown for the Washington University (WU), MRC and Alzheimer's disease Neuroimaging Initiative (ADNI) series.

Table II

	SNP	MAF	Allelic p-value	Geno Freq	Geno p-value
WU	rs1049296	0.15	0.14	0.02/0.27/0.71	0.13
	rs1800562	0.04	0.89	<0.01/0.08/0.92	0.89
MRC	rs1049296	0.15	0.72	0.03/0.25/0.72	0.72
	rs1800562	0.02	0.58	<0.01/0.03/0.97	59
ADNI	rs1049296	0.15	0.61	0.03/0.25/0.72	0.61
	rs1800562	0.01	0.77	<0.01/0.02/0.98	0.72
COMB	rs1049296	0.15	0.46	0.02/0.25/0.72	0.46
	rs1800562	0.02	0.46	<0.01/0.04/0.90	0.45

Table III

rs1049296 and rs1800562 interaction analyses. Synergy Factors (SF) with 95% confidence intervals and p-values for Synergy Factor analysis (SFA) in the Washington University (WU), MRC, Alzheimer's disease Neuroimaging Initiative (ADNI) series, combined sample and combined sample including the initial report by Robson et al. (2004) (All samples) are shown. Adjusted SF (Adj SF) and p-values (Adj SFA p-value) from adjusted SFA including gender, age, *APOE e4* as covariates are also shown.

	SF (95% CI)	SFA p-value	Adj SF (95% CI)	Adj SFA p-value
WU	5.99 (1.82-19.69)	0.0032	2.59 (0.96-6.98)	0.061
MRC	2.46 (0.63-9.59)	0.19	1.72 (0.43-6.81)	0.44
ADNI	2.18 (0.80-5.92)	0.13	1.83 (0.85-3.94)	0.12
Combined	2.71 (1.46-5.05)	0.0016	*2.4 (1.38-4.19)	*0.0020
Robson 2004	5.4 (1.2-19.9)	0.015	NA	**0.014
All samples	2.72 (1.55-4.78)	5.15*10 ⁻³	NA	NA

* Logistic regression analysis for the Combined samples includes adjustments for site, gender *APOE e4* and age.

** P-value from adjusted SFA including age and gender as covariates. Only genotypes counts are available in the Robson et al 2004 manuscript therefore adjusted SFA, which required gender, age and *APOE e4* data were not performed in the all of the samples combined (NA).